$50 million to develop world-leading artificial heart
Posted: 21 February 2024 The Australian Government is providing $50 million to develop and commercialise the world’s most advanced artificial heart, a technology that could halve deaths from heart failure globally and contribute $1.8 billion to Australia and…
VivaGel BV US FDA Appeal Outcome
Posted: 20 February 2024 Starpharma (ASX: SPL, OTCQX: SPHRY) today announces that it has completed the formal dispute resolution process with the US Food and Drug Administration (FDA) in relation to VivaGel® BV. The FDA has maintained its position that…
Effort to cure corneal blindness globally welcomes $35 million support
Posted: 20 February 2024 University of Melbourne researchers addressing the global challenge of corneal blindness – caused by disorders that damage and scar the transparent layer of our eyes – have welcomed a $35 million grant from the…
Major discovery points to more potent, durable RNA-based therapeutics
Posted: 20 February 2024 Australian scientists have made a major discovery that could underpin the next generation of RNA-based therapeutics, and lead to more potent and longer-lasting RNA-based drugs with an even wider array of potential uses. In…
Brandon Biocatalyst in partnership with ANDHealth selected by Federal Government to deliver $50m dementia and cognitive decline incubator
Posted: 20 February 2024 Brandon BioCatalyst’s CUREator, in partnership with ANDHealth, is set to deliver a BioMedTech Incubator (BMTI) focused on developing research discoveries and medical innovations with commercial potential to address dementia and cognitive decline thanks…
Breakthrough heralds immune-personalised medicine for lupus
Posted: 20 February 2024 The immune system is extraordinarily complex and powerful, the primary function of which is to detect and destroy foreign or “non-self” proteins, including infections and cancer. To do this, it’s evolved two parallel sets…
Innovative modelling may help breast cancer patients who don’t respond to treatment
Posted: 20 February 2024 Monash University-led research is using maths to predict how new combination therapies can help patients with breast cancer who no longer respond to conventional therapies. Published in NPJ Precision Oncology , the Monash Biomedicine Discovery Institute (BDI) study…
Immutep appoints Anne Anderson to Board
Posted: 20 February 2024 Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, announces the appointment of Anne Anderson as independent non-executive director (NED)…
Economic Assessment of ANDHealth+ and Masterclass: Accelerate Programs
Posted: 20 February 2024 An independent report into Australian digital health commercialisation programs has highlighted the considerable impact of ANDHealth on core economic metrics when benchmarked against comparable accelerators in general technology, deep technology, and health technology. Published…
OPTISCAN RECEIVES $3 MILLION CRC-P INDUSTRY GRANT
Posted: 14 February 2024 Optiscan Imaging Limited (ASX: OIL) is pleased to announce receiving a $3 million Cooperative Research Centres Projects (CRC-P) grant to work on its Edge-AI-enabled gastrointestinal (GI) endomicroscope. The project worth a total of $9,236,713…
CSL Announces Top-line Results from the Phase 3 AEGIS-II Trial Evaluating the Efficacy and Safety of CSL112 (apolipoprotein A-I [human])
Posted: 14 February 2024 Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) today announced top-line results from the Phase 3 AEGIS-II trial evaluating the efficacy and safety of CSL112 (apolipoprotein A-I [human]) compared to placebo in reducing the risk of…
Noxopharm extends strategic partnership with Hudson Institute of Medical Research
Posted: 14 February 2024 Innovative biotech company Noxopharm Limited (ASX:NOX) is pleased to announce that it has renewed its strategic partnership with Melbourne’s Hudson Institute of Medical Research for a further 12 months. The partnership and in-licensed technology…
